Remdesivir News and Research

RSS

Scientists develop experimental direct-acting antiviral therapy to treat COVID-19

An international team of scientists from the Menzies Health Institute Queensland (MHIQ) at Griffith University and from City of Hope, a research and treatment center for cancer, diabetes and other life-threatening diseases in the U.S., have developed an experimental direct-acting antiviral therapy to treat COVID-19.

18 May 2021

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

A team of scientists from the USA and Belgium has recently revealed that the ErbB family of receptor tyrosine kinases play a vital role in regulating severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lifecycle in host cells and that inhibition of these receptors can protect against SARS-CoV-2-induced acute and chronic lung injuries and inflammation.

18 May 2021

Researchers use ultrasound to reduce COVID-19-related inflammation

Researchers at University of California San Diego School of Medicine have begun a pilot clinical trial to test the efficacy of using ultrasound to stimulate the spleen and reduce COVID-19-related inflammation, decreasing the length of hospital stays.

13 May 2021

Study reveals how oral antiviral drug works to attack SARS-CoV-2 virus

A University of Alberta virology lab has uncovered how an oral antiviral drug works to attack the SARS-CoV-2 virus, in findings published May 10 in the Journal of Biological Chemistry.

12 May 2021

Researchers design compounds that prevent SARS-CoV-2 entry in human lung cells

Researchers have designed a new class of TMPRSS2 inhibitors that have shown broad antiviral activity against coronaviruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

11 May 2021

Researchers discover the second possible effective mechanism of remdesivir

The virostatic agent remdesivir was developed to disrupt an important step in the propagation of RNA viruses, to which SARS-CoV-2 also belongs: the reproduction of the virus's own genetic material. This is present as RNA matrices with which the host cell directly produces virus proteins.

11 May 2021

Researchers identify anti-inflammatory prodrug Minnelide with potential against SARS-CoV-2

Using a transgenic mouse model of COVID-19, they have observed that treatment with Minnelide reduces viral load and inflammation in the lungs and improves survival. The study is currently available on the bioRxiv* preprint server.

9 May 2021

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

An interesting new study describes the emergence of several such variants from a chronically immunosuppressed COVID-19 patient, who remained infected for over 170 days before clearing the virus.

7 May 2021

Researchers identify potent small molecule TMPRSS2 inhibitor against SARS-CoV-2

A team of scientists from the USA and Canada has recently identified and characterized a novel small-molecule compound inhibitor of cellular serine protease TMPRSS2, which shows significant antiviral potency against emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

5 May 2021

Hepatitis C antivirals synergize with remdesivir to inhibit SARS-CoV-2 in vitro

A new study sheds light on the potential of drug combinations to stem viral transmission and treat patients with COVID-19. It also shows that four drugs used to treat hepatitis C synergize with remdesivir to make it up to ten times more effective at inhibiting SARS-CoV-2 in cell cultures.

30 Apr 2021

What is the role of nanotechnology in the current COVID-19 outbreak?

The nanotechnology-based medicine platforms against COVID-19 bears hope for relief from the pandemic to save lives and mitigate the infection as part of a broader global public health agenda.

27 Apr 2021

The potential of CRISPR-based diagnostic assays and treatment approaches against COVID-19

In their review paper recently published in the Indian Journal of Clinical Biochemistry, a group of authors discusses currently available and forthcoming CRISPR-based diagnostic assays, as well as the possibility of using the CRISPR/Cas system as a salient treatment or prevention strategy in the fight against coronavirus disease 2019 (COVID-19).

25 Apr 2021

New Phase 3 trial of therapeutics begins enrolling severely ill hospitalized COVID-19 patients

A new Phase 3 trial to test the safety and efficacy of therapeutics for COVID-19 has begun enrolling patients hospitalized with life-threatening cases of COVID-19, including those with acute respiratory failure.

22 Apr 2021

Shifts in care due to COVID-19 pandemic likely to drive drug expenditures in 2021

The COVID-19 pandemic heavily influenced spending on prescription drugs in the U.S. in 2020, according to the ASHP's (American Society of Health-System Pharmacists) National Trends in Prescription Drug Expenditures and Projections for 2021.

21 Apr 2021

NIH funds large Phase 3 clinical trial to test repurposed drugs for treating COVID-19 symptoms

Using an ACTIV master protocol, the trial will focus on potential interventions for mild-to-moderate illness.

20 Apr 2021

Experimental antiviral drug for COVID-19 shows effectiveness in hamster models

The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from National Institutes of Health scientists.

17 Apr 2021

No evidence B.1.1.7. variant worsens symptoms or increases risk of long COVID

The study, published in The Lancet, demonstrates that there is no evidence of a link between severe illness and death and lineage when comparing the B.1.1.7 lineage and other variants.

14 Apr 2021

Alpaca nanobodies effective against South African SARS-CoV-2 variant

Researchers in South Africa and the UK have identified alpaca-derived nanoantibodies that potently neutralize variants of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

13 Apr 2021

Clinical trial of monoclonal antibody for treating respiratory disease in COVID-19 patients begins

A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun.

13 Apr 2021

Researchers identify SARS-CoV-2 antiviral compounds using protein assay

During the process of SARS-CoV-2 infection, once the virus penetrates the host cell, two open reading frames, ORF1a and ORF1ab, are translated. ORF1ab is responsible for the production of 16 nonstructural proteins (nsp). Several viral proteases such as 3CLpro and PLpro (papain-like protease) produce 1-16 nsps. A new study has been published in bioRxiv* preprint server, which deals with identifying drugs that are effective as PLpro inhibitors.

13 Apr 2021

Remdesivir News and Research

Scientists develop experimental direct-acting antiviral therapy to treat COVID-19

ErbB inhibitor lapatinib exhibits potent anti-SARS-CoV-2 activity

Researchers use ultrasound to reduce COVID-19-related inflammation

Study reveals how oral antiviral drug works to attack SARS-CoV-2 virus

Researchers design compounds that prevent SARS-CoV-2 entry in human lung cells

Researchers discover the second possible effective mechanism of remdesivir

Researchers identify anti-inflammatory prodrug Minnelide with potential against SARS-CoV-2

Immunosuppression in COVID-19 promotes emergence of multiple immune escape mutants

Researchers identify potent small molecule TMPRSS2 inhibitor against SARS-CoV-2

Hepatitis C antivirals synergize with remdesivir to inhibit SARS-CoV-2 in vitro

What is the role of nanotechnology in the current COVID-19 outbreak?

The potential of CRISPR-based diagnostic assays and treatment approaches against COVID-19

New Phase 3 trial of therapeutics begins enrolling severely ill hospitalized COVID-19 patients

Shifts in care due to COVID-19 pandemic likely to drive drug expenditures in 2021

NIH funds large Phase 3 clinical trial to test repurposed drugs for treating COVID-19 symptoms

Experimental antiviral drug for COVID-19 shows effectiveness in hamster models

No evidence B.1.1.7. variant worsens symptoms or increases risk of long COVID

Alpaca nanobodies effective against South African SARS-CoV-2 variant

Clinical trial of monoclonal antibody for treating respiratory disease in COVID-19 patients begins

Researchers identify SARS-CoV-2 antiviral compounds using protein assay

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News